Troglitazone
(Redirected from Resulin)
Troglitazone (brand name: Rezulin) was the inaugural thiazolidinedione introduced for treatment in the United States for managing type 2 diabetes. It was greenlit by the FDA in 1997. However, due to subsequent concerns and findings regarding its potential to cause liver injury and the incidences of acute liver failure, the drug was officially withdrawn from the market in 2000.
Mechanism of Action[edit | edit source]
Troglitazone functions as an insulin-sensitizing agent. Its primary mechanism revolves around the activation of PPAR-γ (Peroxisome proliferator-activated receptor gamma) receptors. Activation of these receptors triggers the expression of numerous genes that play pivotal roles in the metabolic processes of glucose and fatty acids. Clinical trials conducted on the drug demonstrated its efficacy in reducing both blood glucose and HbA1c levels. Moreover, when combined with antidiabetic agents like sulfonylureas and metformin, troglitazone was shown to have synergistic effects.
FDA Approval and Withdrawal[edit | edit source]
After its FDA approval in 1997, Troglitazone emerged as a promising agent in the arsenal against type 2 diabetes. It could be administered as a standalone treatment or paired with other antidiabetic medications to bolster its effects. Nevertheless, its promise was short-lived. Only a few years after its widespread commercial release, there was a surge in reports indicating severe liver injuries associated with Troglitazone usage, including some fatal instances of acute liver failure. The alarming rate and severity of these reports hastened the drug's withdrawal in 2000.
Dosage and Administration[edit | edit source]
Troglitazone was commercialized in the form of 400 mg tablets. The prescribed dosage for patients typically ranged from 400 to 800 mg, taken once daily. It could be prescribed as a sole therapeutic agent or in conjunction with other medications such as metformin, sulfonylureas, or insulin, based on the individual's glycemic control requirements.
See also[edit | edit source]
Thiazolidinedione Type 2 diabetes FDA Metformin Sulfonylureas Liver failure PPAR-γ receptors Antidiabetics
- Alpha-Glucosidase Inhibitors
- Incretin-Based Drugs
- Insulin
- Metformin
- Metiglinide Analogues
- Pramlintide
- Sodium Glucose Cotransporter-2 (SGLT-2) Inhibitors
- Sulfonylureas
- First Generation Sulfonylureas
- Acetohexamide
- Chlorpropamide
- Tolazamide
- Tolbutamide
- Second Generation Sulfonylureas
- Gliclazide
- Glimepiride
- Glipizide
- Glyburide (Glibenclamide)
- First Generation Sulfonylureas
- Thiazolidinediones
Troglitazone Resources | |
---|---|
|
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
WikiMD's Wellness Encyclopedia |
Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD